How Advanced Drug Delivery Could Improve Existing Cancer Treatments [Video Edition]

About this episode

The episode discusses how advanced drug delivery technologies are being utilized to improve existing cancer treatments amidst rising drug development costs and complex regulatory pathways.

BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy centers on leveraging platform technologies that may support multiple therapeutic applications across oncology and rare disease markets rather than relying solely on a single drug candidate. Oncotelic is one of several companies, including Northwest…

Topics covered

• advanced drug delivery
• cancer treatments
• biotechnology
• nanoparticle delivery systems
• oncology
• therapeutics

Keywords

• oncology
• drug delivery
• biotechnology
• nanotechnology
• cancer therapies
• bioavailability
• therapeutics

Mentioned in this episode

Organizations: Oncotelic Therapeutics Inc., Northwest Biotherapeutics Inc., Sangamo Therapeutics Inc., HIVE Digital Technologies Ltd., Iovance Biotherapeutics Inc.

Products: Sapu003, Deciparticle(TM)

More episodes of The BioMedWire Podcast

• How Advanced Drug Delivery Could Improve Existing Cancer Treatments · June 5, 2026 · 21 min
• BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) · June 2, 2026 · 17 min
• BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) [Video Edition] · June 2, 2026 · 17 min
• CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities · May 15, 2026 · 20 min
• CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities [Video Edition] · May 15, 2026 · 20 min
• The Next Generation of the GLP-1 Revolution Is Already Underway · May 15, 2026 · 22 min